On October 18, 2022, William Mann, Ph.D., president and chief operating officer of NeuBase Therapeutics, Inc., notified the company of his intent to resign from the company, effective October 31, 2022. Dr. Mann's resignation is not a result of any disagreement with the company on any matter relating to the company's policies or procedures.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.378 USD | -3.20% | -.--% | -48.93% |
1st Jan change | Capi. | |
---|---|---|
+35.09% | 51.07B | |
-7.50% | 38.78B | |
+35.88% | 38.61B | |
-10.62% | 27.32B | |
+12.13% | 26.35B | |
-17.51% | 19.46B | |
+41.52% | 13.58B | |
+30.92% | 12.46B | |
-2.94% | 11.75B |
- Stock Market
- Equities
- O7P Stock
- NBSE Stock
- News NeuBase Therapeutics, Inc.
- NeuBase Therapeutics, Inc. Announces Resignation of William Mann as President and Chief Operating Officer, Effective October 31, 2022